Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
life sciences
national blog main
new york blog main
new york top stories
9
×
boston top stories
national top stories
biotech
clinical trials
fda
san francisco blog main
san francisco top stories
new york
sanofi
startups
alnylam pharmaceuticals
amgen
biogen
boston
cancer
deals
inclisiran
ipo
novartis
regeneron pharmaceuticals
venture capital
blackstone group
boulder/denver blog main
boulder/denver top stories
cholesterol
david goldstein
deerfield management
depression
detroit blog main
detroit top stories
drug discovery
epilepsy
essential tremor
europe blog main
europe top stories
What
medicines
9
×
new
ceo
cholesterol
drug
drugs
fda
ipo
medco
research
aims
announced
bio
covid
deal
developing
lowering
morning
praxis
precision
roundup
touting
twice
aces
acquire
acquisitions
activity
agreed
approach
approvals
backed
based
big
billion
biogen
biotech
biotechs
bringing
brings
called
Language
unset
9
×
Current search:
medicines
×
unset
×
" new york top stories "
×
@xconomy.com
3 years ago
Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs
@xconomy.com
3 years ago
Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Schrödinger Sets Course for IPO to Support Growing Internal Pipeline
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
MedCo Preps for FDA Filing as Cholesterol Drug Clears Last Two Tests
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing